Equillium, Inc. (EQ) is a biopharmaceutical company with a focus on developing novel therapies for severe autoimmune and inflammatory disorders. Founded in 2017 and based in La Jolla, California, the company's primary goal is to develop products that can restore the balance of the immune system to treat a range of conditions, and to leverage deep knowledge of immunology and immune-mediated diseases in order to deliver innovative medicines to patients who need them most.
The company’s lead product candidate is Itolizumab (EQ001). Itolizumab is an anti-CD6 monoclonal antibody that is currently in the later stages of clinical trials for various autoimmune and inflammatory diseases. These include acute graft versus host disease, uncontrolled asthma, and lupus nephritis among others. Equillium holds exclusive worldwide rights to Itolizumab, and its aim is to demonstrate this novel therapy’s potential in treating multiple severe diseases where the CD6-ALCAM pathway plays a key role in the immune response.
It's important to note that Equillium's approach to innovative biopharmaceuticals extends beyond just one product. The company places considerable emphasis on discovery and research, exploring new therapeutic areas and novel approaches to existing challenges. This constantly evolving therapeutic pipeline strengthens Equillium’s overall potential for growth and its capacity to bring new treatments to market.
In the business world, Equillium is known for its strong leadership team, which includes seasoned professionals with substantial experience in the biotech industry. The team uses their extensive grasp of immunology, regulatory affairs, and commercial strategy to propel the company toward its goal of developing and commercializing its novel therapies.
On the financial side, Equillium made its initial public offering (IPO) in October 2018. Since then, the company has been backed by several institutional investors, which confirms confidence in the company's mission and potential.
Overall, Equillium, Inc. is recognized for its relentless dedication to science and innovation, a strong business strategy, and a commitment to addressing some of the most significant unmet medical needs in the world today. Through its rigorous and deliberate approach to drug discovery and development, the company continues to drive progress in the treatment of autoimmune and inflammatory diseases.